Research analysts at Roth Capital began coverage on shares of Cytori Therapeutics (NASDAQ: CYTX) in a report released on Wednesday. The firm set a “buy” rating and a $8.00 price target on the stock.
Cytori Therapeutics opened at 2.69 on Wednesday. Cytori Therapeutics has a 1-year low of $2.01 and a 1-year high of $4.93. The stock’s 50-day moving average is currently $2.69. The company’s market cap is $158.3 million.
Separately, analysts at Ascendiant Capital Markets initiated coverage on shares of Cytori Therapeutics in a research note to investors on Wednesday, February 20th. They set a “buy” rating and a $3.25 price target on the stock.
Cytori Therapeutics, Inc. develops, manufactures, and sells medical products and devices to enable the practice of regenerative medicine.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
